Therapeutic B-cell depletion reverses progression of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
The function of B cells in Alzheimer’s disease (AD) is not fully understood. While immunoglobulins that target amyloid beta (Aβ) may interfere with plaque formation and hence progression of the disease, B cells may contribute beyond merely producing immunoglobulins. Here we show that AD is associated with accumulation of activated B cells in circulation, and with infiltration of B cells into the brain parenchyma, resulting in immunoglobulin deposits around Aβ plaques. Using three different murine transgenic models, we provide counterintuitive evidence that the AD progression requires B cells. Despite expression of the AD-fostering transgenes, the loss of B cells alone is sufficient to reduce Aβ plaque burden and disease-associated microglia. It reverses behavioral and memory deficits and restores TGFβ + microglia, respectively. Moreover, therapeutic depletion of B cells at the onset of the disease retards AD progression in mice, suggesting that targeting B cells may also benefit AD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings collectively highlight a complex and stage-dependent dynamic of B cell involvement in experimental models of AD.”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transient depletion of B cells in the 5xFAD model of AD, using either anti-CD20 or a mix of anti-CD20/B220 antibodies led to different pathological outcomes [107,108].”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This implies that the balance between regulatory and effector B cell subsets, rather than the presence or absence of B cells per se, is the critical determinant of outcome.”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation and systemic expansion of specific B cell subsets (e.g., B1a and B1b), along with their cytokine-producing phenotype, further implicates B cells in neuroinflammatory and immunomodulatory processes during AD pro gression.”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All together, these three scenarios suggest that the dual role of B cells in AD is not a paradox but rather the product of heterogeneity in B cell subset identity, disease stage, and anatomical compartment.”
From Is there a role for B cells in Alzheimer's disease? (2026) · cites this paper as [108]
Experimental — accuracy not yet measured
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 65 · Cited by 206
Metadata
- Authors
- Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., & Biragyn, A.
- Affiliations
- National Institute on Aging (US)
- Bar-Ilan University (IL)
- Russian Academy of Sciences (RU)
- National Institutes of Health (US)
- Corresponding author
- Biragyn, Arya
- ORCID
- Venue
- Nature Communications
- Published
- 2021-04-12
- Volume
- 12
- Issue
- 1
- Pages
- 2185-2185
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8042032
- OpenAlex
- W3153691873
- Cited by
- 206
- References
- 65
- Citations by year
- 2026: 22 · 2025: 51 · 2024: 57 · 2023: 25 · 2022: 41 · 2021: 10
- FWCI
- 21.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG000778-04)
- U.S. Department of Health & Human Services | NIH | Center for Information Technology (AG054712-01A1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, B cells, B-cell depletion, amyloid plaques, immunoglobulin deposits, microglia, TGF-beta, memory impairment, disease progression, therapeutic targeting, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Animals, B-Lymphocytes, Female, Hippocampus, Humans, Lymphocyte Depletion, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Phenotype, Transforming Growth Factor beta, Amyloid beta-Peptides, Microglia, Disease Progression, Mice, Interleukin-1beta, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41467-021-22479-4
- The paper
- Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., & Biragyn, A. (2021). Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. Nature Communications. https://doi.org/10.1038/s41467-021-22479-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.